What Is Retatrutide?

Also known as: Triple agonist, LY3437943

Retatrutide is Eli Lilly's investigational 'triple G' agonist, hitting GLP-1, GIP and glucagon receptors simultaneously. The glucagon arm adds increased energy expenditure to the appetite-suppression playbook — the body burns more while eating less.

Phase 2 results were unprecedented: roughly 24% average weight loss at 48 weeks, with the curve still declining at study end. It is widely expected to become the most potent obesity medication ever approved — but it is not approved yet, and everything sold today is unregulated research material.

What is Retatrutide studied for?

Side effects & safety

Trial-reported: the familiar GI cluster, plus dose-dependent heart-rate increases attributed to the glucagon arm — the main thing phase 3 is watching. Outside trials, the biggest risk is simply that no approved dosing or safety framework exists.

Legal & approval status

Investigational — no approval anywhere. Sold only as a research chemical; anyone using it is effectively self-enrolling in an uncontrolled experiment.

Typical dosing at a glance

Commonly reported protocols use 1 mg–12 mg, 1x weekly, titrated up, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the Retatrutide reconstitution calculator →

Related peptides

What is Semaglutide?What is Tirzepatide?What is Cagrilintide?What is AOD-9604?What is HGH Fragment 176-191?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.